ReviewBriefings in bioinformatics2026
The next paradigm in bioinformatics: a review of multi-agent systems and foundational models for end-to-end scientific discovery.
Review in Briefings in bioinformatics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Trustworthy Agentic AI in Bioinformatics: From Workflow Automation to Traceable and Validated Biological Inference.Biology · 2026Review
- Opportunities and Risks of Technology Convergence in Precision Health.Blockchain in healthcare today · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bioinformatics is entering a new phase characterized by the integration of universal biological models and multi-agent systems to enable end-to-end scientific discoveries. This review argues that the next paradigm shift will go beyond traditional predictive models and generative artificial intelligence (AI) toward agentic AI: systems capable of planning, acting through tools, reflecting on results, and iterating until a goal is achieved. We first examine recent foundational models that produce transferable representations across omic modalities, such as scGPT, Nicheformer, and EpiAgent, and discuss their architectural choices, training regimes, and interpretability constraints. We then analyze biomedical agent frameworks through their main components (planning, action, reflection, and memory), highlighting representative systems such as ClinicalAgent and Biomni that operationalize these ideas in controlled environments. Next, we focus on hypothesis validation mechanisms, including retrieval-augmented generation for evidence grounding, sequential statistical testing, and benchmarking methodologies designed to quantify robustness and reproducibility. Finally, we summarize emerging applications in drug discovery and personalized medicine, from molecular literature analysis and protocol automation to drug repurposing for rare diseases and closed-loop synthesis. We conclude by outlining the main challenges ahead, namely hallucinations, interpretability, systemic biases, integration with clinical infrastructures, and regulatory and ethical requirements, and propose a roadmap for the development of scientific agents that are not only high-performing but also reliable, verifiable, and implementable in real biomedical contexts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.